Amicus Therapeutics (NASDAQ:FOLD) Receives “Neutral” Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated their neutral rating on shares of Amicus Therapeutics (NASDAQ:FOLD) in a research report report published on Friday morning,Benzinga reports. Cantor Fitzgerald currently has a $14.50 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $21.00.

A number of other brokerages have also commented on FOLD. Wall Street Zen upgraded shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. The Goldman Sachs Group raised their target price on shares of Amicus Therapeutics from $9.00 to $11.00 and gave the stock a “neutral” rating in a report on Wednesday, November 5th. Citigroup began coverage on shares of Amicus Therapeutics in a research report on Wednesday. They issued a “buy” rating and a $17.00 target price for the company. Needham & Company LLC raised Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a report on Thursday, September 18th. Finally, Zacks Research upgraded Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 6th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Amicus Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $16.36.

Amicus Therapeutics Stock Up 30.4%

FOLD stock opened at $14.20 on Friday. The stock has a market capitalization of $4.38 billion, a P/E ratio of -354.81 and a beta of 0.46. The company has a debt-to-equity ratio of 1.70, a current ratio of 2.99 and a quick ratio of 2.09. Amicus Therapeutics has a 1-year low of $5.51 and a 1-year high of $14.36. The business has a fifty day moving average price of $9.48 and a 200-day moving average price of $7.82.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.12 by $0.05. Amicus Therapeutics had a positive return on equity of 6.95% and a negative net margin of 2.35%.The company had revenue of $169.06 million for the quarter, compared to analysts’ expectations of $165.24 million. During the same period last year, the firm posted $0.10 earnings per share. Amicus Therapeutics’s revenue was up 19.5% compared to the same quarter last year. Equities analysts forecast that Amicus Therapeutics will post 0.15 earnings per share for the current fiscal year.

Insider Buying and Selling at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 77,926 shares of the company’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $10.86, for a total value of $846,276.36. Following the completion of the sale, the chief executive officer directly owned 1,129,782 shares in the company, valued at $12,269,432.52. This represents a 6.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Jeff Castelli sold 76,158 shares of the firm’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $10.16, for a total value of $773,765.28. Following the completion of the transaction, the insider directly owned 439,318 shares in the company, valued at approximately $4,463,470.88. This represents a 14.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 319,808 shares of company stock valued at $3,293,653 over the last three months. Insiders own 2.20% of the company’s stock.

Institutional Trading of Amicus Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of FOLD. Vestal Point Capital LP raised its stake in shares of Amicus Therapeutics by 178.4% in the second quarter. Vestal Point Capital LP now owns 11,900,000 shares of the biopharmaceutical company’s stock worth $68,187,000 after buying an additional 7,625,000 shares during the period. Norges Bank bought a new stake in Amicus Therapeutics during the 2nd quarter worth approximately $18,540,000. Assenagon Asset Management S.A. lifted its holdings in Amicus Therapeutics by 641.2% during the second quarter. Assenagon Asset Management S.A. now owns 3,533,854 shares of the biopharmaceutical company’s stock valued at $20,249,000 after purchasing an additional 3,057,072 shares in the last quarter. Millennium Management LLC boosted its position in shares of Amicus Therapeutics by 635.1% in the first quarter. Millennium Management LLC now owns 3,359,389 shares of the biopharmaceutical company’s stock worth $27,413,000 after purchasing an additional 2,902,375 shares during the period. Finally, Redmile Group LLC boosted its position in shares of Amicus Therapeutics by 35.1% in the first quarter. Redmile Group LLC now owns 9,533,669 shares of the biopharmaceutical company’s stock worth $77,795,000 after purchasing an additional 2,478,779 shares during the period.

Trending Headlines about Amicus Therapeutics

Here are the key news stories impacting Amicus Therapeutics this week:

• Positive Sentiment: BioMarin to acquire Amicus for ~$4.8B ($14.50 per share), citing complementary marketed products (Galafold, Pombiliti + Opfolda), $599M of recent revenue and expectations the deal will be accretive to non‑GAAP EPS within 12 months — this provides a clear exit price and strategic rationale that pushed the stock up. Article Title
• Positive Sentiment: BioMarin’s press release emphasizes revenue upside from bringing Amicus products into BioMarin’s global footprint and resolving pending patent litigation on Galafold — details that support the acquisition valuation and near-term revenue accretion view. Article Title
• Neutral Sentiment: Trading was temporarily halted pre-market for “news pending,” then resumed around the acquisition announcement — a procedural sign the market treated the item as material. (Trading halt noted in market alerts.)
• Neutral Sentiment: Cantor Fitzgerald reaffirmed a “neutral” rating with a $14.50 price target (roughly in line with the deal price), and Needham reiterated a “hold” — analyst stances imply limited upside beyond the announced offer price absent a competing bidder. Article Title
• Negative Sentiment: Two investor‑rights firms (Halper Sadeh LLC and The Ademi Firm) announced investigations into whether the $14.50 per‑share sale is fair to Amicus shareholders — litigation or proxy fights could delay closing, pressure timing, or open the door to a higher bid/renegotiation, increasing deal execution risk. Article Title
• Negative Sentiment: Insider selling disclosures (including recent sales by the CEO and another officer) surfaced in filings earlier this week — while not unusual, these sales add a note of caution for some investors evaluating management alignment ahead of the deal. Article Title

Amicus Therapeutics Company Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.